BRIEF published on 04/15/2025 at 10:05, 1 year 1 month ago IOmx Therapeutics Gains Approval for IOMX-0675 Clinical Trials Immune Response IOmx Therapeutics IOMX-0675 Clinical Trial Approval Solid Tumor Therapy
BRIEF published on 04/15/2025 at 10:05, 1 year 1 month ago IOmx Therapeutics obtient l'approbation pour les essais cliniques sur IOMX-0675 Réponse Immunitaire IOmx Therapeutics IOMX-0675 Approbation Des Essais Cliniques Thérapie Des Tumeurs Solides
PRESS RELEASE published on 04/15/2025 at 10:00, 1 year 1 month ago iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675 iOmx Therapeutics receives regulatory approval for clinical trial application of IOMX-0675, a LILRB1/LILRB2 dual-targeting antibody, to reverse immune suppression in solid tumors Regulatory Approval Clinical Trial Application IOmx Therapeutics IOMX-0675 Solid Tumor
BRIEF published on 12/19/2024 at 14:05, 1 year 5 months ago IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application Cancer Treatment Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors
BRIEF published on 12/19/2024 at 14:05, 1 year 5 months ago IOmx Therapeutics fait progresser IOMX-0675 avec une application d'essai clinique Traitement Du Cancer Thérapeutique IOmx IOMX-0675 Demande D'essai Clinique Récepteurs Immunosuppresseurs
PRESS RELEASE published on 12/19/2024 at 14:00, 1 year 5 months ago iOmx Therapeutics submits Clinical Trial Application for IOMX-0675 iOmx Therapeutics submits Clinical Trial Application for IOMX-0675, a dual-targeting antibody demonstrating strong anti-tumor potential by reprogramming myeloid cells and restoring cytotoxic T cell function Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors Anti-tumor Potential
BRIEF published on 08/22/2024 at 10:05, 1 year 9 months ago IOmx Therapeutics Initiates Phase Ib with OMX-0407 Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 08/22/2024 at 10:05, 1 year 9 months ago IOmx Therapeutics lance la phase Ib avec OMX-0407 Essai Clinique Thérapie Contre Le Cancer OMX-0407 Phase Ib Thérapeutique IOmx
PRESS RELEASE published on 08/22/2024 at 10:00, 1 year 9 months ago iOmx Therapeutics Initiates Phase Ib with OMX-0407 iOmx Therapeutics initiates Phase Ib clinical trial with OMX-0407, showing favorable safety profile and anti-tumor activity in solid tumors. Expansion phase opens in kidney cancer and angiosarcoma Solid Tumors Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 06/27/2024 at 10:05, 1 year 10 months ago IOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer Chief Financial Officer Biopharmaceutical Leadership IOmx Therapeutics Florian Schmid
Published on 05/23/2026 at 19:45, 23 hours 6 minutes ago Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 1 day 15 hours ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 1 day 15 hours ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 1 day 16 hours ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 1 day 16 hours ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/24/2026 at 12:25, 6 hours 25 minutes ago AutoFlight V5000 Matrix Concludes 'Heterogeneous Three-Aircraft Formation' Flight, Officially Kicks Off Airworthiness Certification
Published on 05/24/2026 at 05:55, 12 hours 55 minutes ago The 26th CIFIT to Open in Xiamen This September, Preceded by Successful Guangzhou Roadshow
Published on 05/24/2026 at 05:35, 13 hours 15 minutes ago CGTN: Xizang at 75: Development and culture create a 'miracle on Earth'
Published on 05/23/2026 at 16:30, 1 day 2 hours ago HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 1 day 2 hours ago EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 19:35, 1 day 23 hours ago PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 2 days ago Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 2 days ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 2 days 5 hours ago Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 2 days 5 hours ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
